Original Article

Vol. 25 No. 1 (2021): Endocrinology Research and Practice

Clinical Spectrum and Outcome of Patients with Graves’ Disease: A Single-Center Experience from a Tertiary Care Institution in the Kashmir Valley, India

Main Article Content

Mohammad Hayat BHAT
Javaid Ahmad BHAT
Shariq Rashid MASOODI
Waseem QURESHI
Junaid Rashid DAR
Moomin Hussain BHAT

Abstract

ABSTRACT



Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treat-ment outcome of GD in the post-iodization scenario. Material and Met-hods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 females and 53 males) attending our center were reviewed retrospectively. The demographic data, modes of tre-atment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with antithyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagno-sis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/ or goiter, although the aty-pical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remis-sion. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On fol-low-up at three months, 46.1% of the patients were euthyroid, with nor-malization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical the-rapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly asso-ciated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accu-rate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.



 



 


Article Details